ADC Therapeutics reports sufficient cash reserves through 2028 while evaluating next steps for its LOTIS-5 program.
ADC Therapeutics (ADCT) announced its cash runway now extends into 2028, providing financial flexibility as it assesses the regulatory path for LOTIS-5. The update follows Q2 2026 earnings commentary, where management noted ZYNLONTA’s commercial performance remained consistent with prior quarters.
The company did not disclose specific revenue figures but emphasized stability in its core product’s market position. Prior quarters showed modest growth, though regulatory hurdles for pipeline assets have posed challenges. LOTIS-5’s development timeline remains under review.
No immediate market reaction was detailed in the earnings call summary. ADCT shares have faced volatility amid pipeline uncertainties in recent months.